Glenn Goddard

Vice President, Finance, Agios Pharmaceuticals.

Companies

Intellia TherapeuticsChief financial officer Dec 20, 2018 to Mar 5, 2024¹
Intellia TherapeuticsOfficer Oct 29, 2018 to Dec 20, 2018²
Agios PharmaceuticalsVice President, Finance Jul 23, 2013 to Feb 18, 2016³

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Intellia Therapeutics NTLA69,213 shares⁴$794.6K at $11.48Mar 1, 2024

As of each latest filing. The line shows shares held over time.

Recent filings

Mar 1, 2024Granted 28,628 shares of Intellia Therapeutics⁴
Jan 3, 2024Sold 5,365 shares at $29.46 of Intellia Therapeutics⁵
Jan 1, 2024Exercised options 3,062 shares of Intellia Therapeutics⁶
Mar 1, 2023Granted 27,484 shares of Intellia Therapeutics⁷
Jan 4, 2023Sold 2,427 shares at $37.21 of Intellia Therapeutics⁸
Jan 1, 2023Exercised options 3,062 shares of Intellia Therapeutics⁹
Mar 1, 2022Granted 12,720 shares of Intellia Therapeutics¹⁰
Jan 1, 2022Sold 1,013 shares at $112.24 of Intellia Therapeutics¹⁰
Jan 1, 2022Exercised options 3,062 shares of Intellia Therapeutics¹⁰

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARIntellia Therapeutics, Chief financial officer
2
SEC EDGARIntellia Therapeutics, Officer
3
SEC EDGARAgios Pharmaceuticals, Vice President, Finance
4
SEC EDGARIntellia Therapeutics shares after the filing of Mar 1, 2024
5
SEC EDGARForm 4 filed Jan 5, 2024
6
SEC EDGARForm 4 filed Jan 3, 2024
7
SEC EDGARForm 4 filed Mar 3, 2023
8
SEC EDGARForm 4 filed Jan 6, 2023
9
SEC EDGARForm 4 filed Jan 4, 2023
10
SEC EDGARForm 4 filed Mar 3, 2022